The Types segment classifies scutellarin products by source and formulation, each influencing manufacturing cost and market penetration. Primary types include raw plant extract, which retains the full phytochemical matrix but yields lower purity; purified scutellarin, obtained through chromatography and representing the bulk of injectable and oral dosage forms; synthetic analogues, engineered to enhance bioavailability and currently occupying a niche research niche; and advanced formulations such as liposomal encapsulation, sustained‑release tablets, and transdermal patches, which address solubility constraints and improve patient compliance. Within purified scutellarin, sub‑categories are bulk powder for contract manufacturing, GMP‑certified API for regulated markets, and specialty grade for clinical trials. These type distinctions shape pricing tiers and determine the proportional contribution of each to the overall scutellarin market, with purified API alone generating roughly two‑thirds of total sales. Forecasts indicate that advanced formulations will capture an additional 12 % of the market by 2030, driven by higher reimbursement rates for controlled‑release products, while raw extract volumes are projected to decline modestly as regulatory scrutiny tightens on botanical consistency.
